UltraShape(TM) Granted Health Canada License to Sell CONTOUR I System

    UltraShape Signs Exclusive Canadian Distribution Agreement with
Coherent-AMT Inc.

    YOQNEAM, ISRAEL & SAN RAMON, CALIF., May 4 /CNW/ - UltraShape announced
today that it has been granted a medical device license to sell the
UltraShape(TM) CONTOUR I system for non-invasive fat emulsification for the
purpose of aesthetic body contouring in accordance with Health Canada's
medical device regulations. UltraShape is the first clinically proven
non-invasive solution for body contouring based on focused ultrasound
technology. It has been demonstrated to deliver durable and measurable
circumference and fat thickness reduction in a single treatment and
incremental reduction with multiple treatments.

    "The authorization to sell the UltraShape CONTOUR I system in Canada
represents a key milestone as we establish ourselves as the leader in the
non-invasive body contouring market in North America," said Rodger Stewart,
President and Chief Executive Officer of UltraShape Inc. "Additionally, with
the exclusive distribution agreement with Coherent-AMT Inc., we expect rapid
adoption of the UltraShape(TM) procedure in the Canadian marketplace,
consistent with the clinical and commercial success we have experienced in 45
countries around the world."

    Coherent-AMT Inc. is Canada's leader in aesthetic solutions representing
best of class aesthetic technologies and products for the Canadian market. In
signing an exclusive national distribution agreement with the company,
UltraShape now has access to the largest direct sales, service and support
system in Canada.

    "We see significant demand for a non-invasive body contouring procedure
that gives patients the option of undergoing a painless treatment for the
reduction of localized fat deposits with no downtime and no required
maintenance," explained Dan Webb, Chief Executive Officer of Coherent-AMT Inc.
"Combined with the high interest we have seen from leading aesthetic
clinicians across the country, we are confident UltraShape will become a core
procedure within aesthetic medical practices."

    UltraShape and Coherent-AMT Inc. will immediately begin conducting
clinician training and educational workshops across Canada. For more
information, please contact Coherent-AMT Inc. at (800) 668-5236 or visit
www.aspirebecome.com/physician.

    About the UltraShape CONTOUR I

    The UltraShape(TM) CONTOUR I system, based on patented focused ultrasound
technology, is the first clinically proven non-invasive body contouring
solution for both men and women. It is designed to target and disrupt fat,
leaving surrounding structures such as skin, blood vessels, and nerves intact.
The UltraShape(TM) procedure is guided by proprietary real-time tracking and
guidance software designed to deliver smooth, uniform body contouring results.
The software guarantees adherence to a pre-determined treatment algorithm,
minimizing the risk of contour irregularities, a common side effect of
liposuction which is a highly technique-sensitive surgical procedure.

    The UltraShape procedure is performed during a convenient, "walk-in,
walk-out" session carried out in an office-based environment; it requires no
anesthesia or sedation, and the vast majority of patients report no pain or
discomfort. After treatment, patients immediately resume their daily routines
and there is no need for maintenance treatments.

    About UltraShape

    UltraShape Ltd., founded in 2000, is a privately held and venture backed
company that develops, manufactures and markets innovative, non-invasive
solutions for the aesthetic medical field. The UltraShape expert team is
dedicated to the development of cutting-edge body-contouring technology in a
mission to enhance patients' self-image and sense of well-being. The
UltraShape(TM) CONTOUR I, the first clinically proven non-invasive body
contouring solution based on focused ultrasound technology, received the CE
Mark in June 2005 and is currently distributed in 45 countries outside the
United States. Over 30,000 commercial treatments have been performed worldwide
with high patient satisfaction.

    The concept behind the company's platform technology was developed by Ami
Glicksman, M.D., a plastic surgeon and Yoram Eshel, Ph.D., MBA, a medical
physicist who teamed up to marry the aesthetic clinical experience of the
doctor and the expertise in high power focused ultrasound of the physicist.

    UltraShape adheres to the highest scientific and quality standards and is
ISO 13485: 2003 certified. The company has worldwide offices in the United
States, Israel, France, United Kingdom, and Italy. The UltraShape(TM) CONTOUR
I system is not cleared by the FDA for marketing in the United States.

    For more information, please visit www.ultrashape.com.

For further information: UltraShape Abigail Marks, +972.4.909.9260
Abigail@ultrashape.com or FischerHealth Amanda McNulty Sheldon, 310-577-7870 x
173 asheldon@fischerhealth.com or Porter Novelli Dariela Roffe,
+44.207.853.2234 Dariela.roffe@porternovelli.co.uk